Fenbendazole and Pancreatic Cancer

Fenbendazole and Pancreatic Cancer. Can a veterinary dewormer help fight one of the deadliest cancers?

Interest in fenbendazole and pancreatic cancer has increased in recent years as researchers explore whether existing drugs might be repurposed to fight difficult cancers.

Fenbendazole is an anti-parasitic medication commonly used in veterinary medicine to treat intestinal worms in animals. Some laboratory research suggests it may have anticancer properties, which has led scientists and patients to investigate whether it could play a role in treating cancers such as pancreatic cancer.

But what does the research actually show?

Below is a review of the current evidence, potential mechanisms, and limitations of the science surrounding fenbendazole and cancer.

For pancreatic cancer patients exploring complementary or repurposed therapies, it is important to understand what the research actually shows—and what it does not.

Below is an evidence-based overview of fenbendazole and pancreatic cancer.

I am a long-term survivor of an incurable blood cancer called multiple myeloma. I have gone to great lengths beyond conventional, FDA-approved therapies and taken great risks in an effort to manage my blood cancer.  I can understand why cancer patients hear about non-conventional therapies and want to understand more about them as possible therapies.

The post below is PeopleBeatingCancer’s effort to weigh in on the fenben and thyroid cancer debate. Please scroll down the page, post a question or a comment if you have any questions.

If you’d like to learn more about repurposed drugs and cancer treatment, click now. 

Thank you,

David Emerson

• Cancer Survivor
• Cancer Coach
• Director PeopleBeatingCancer

---

What Is Fenbendazole?

Fenbendazole belongs to a class of drugs called benzimidazole anthelmintics, medications that kill parasitic worms by interfering with cellular structures called microtubules.

Microtubules are essential structures inside cells that help with:

• cell division
• intracellular transport
• maintaining cell shape

Because cancer cells divide rapidly, drugs that disrupt microtubules can sometimes inhibit tumor growth. Many approved chemotherapy drugs (such as taxanes and vinca alkaloids) work through similar mechanisms.

However, fenbendazole is not approved for human use and remains a veterinary drug.

How Fenbendazole Could Treat Cancer (and Why It Won’t)

---

Why Researchers Are Studying Fenbendazole for Cancer

Scientists are increasingly interested in drug repurposing—testing existing medications for new uses. Repurposed drugs are attractive because they:

• are often inexpensive
• have known safety profiles in animals or humans
• can reach clinical trials faster

Benzimidazole drugs such as fenbendazole, mebendazole, and albendazole have demonstrated anticancer activity in laboratory research. These drugs can:

• disrupt microtubule polymerization
• cause cell-cycle arrest
• trigger programmed cell death (apoptosis)
• interfere with cancer metabolism

These mechanisms make them potential candidates for cancer therapy.

---

Potential Anticancer Mechanisms of Fenbendazole

Several laboratory studies have explored how fenbendazole might affect cancer cells.

1. Disrupting microtubules

Fenbendazole interferes with tubulin, the protein that forms microtubules. When microtubules are destabilized, cancer cells may lose the ability to divide and eventually die.

2. Activating tumor-suppressor pathways

Research has shown fenbendazole can trigger activation of p53, a protein that helps cells repair DNA damage or undergo apoptosis when damage is severe.

3. Blocking cancer cell metabolism

Some studies indicate fenbendazole may reduce glucose uptake by cancer cells by affecting glucose transporters and glycolytic enzymes. Because tumors rely heavily on glucose for energy, this could potentially “starve” cancer cells.

4. Triggering cancer cell death

By interfering with microtubules and cellular metabolism simultaneously, fenbendazole may activate multiple pathways that lead to cancer cell death.

---

Research Evidence: Fenbendazole and Cancer

Most of the evidence supporting fenbendazole as an anticancer therapy comes from laboratory and animal studies, not human clinical trials.

A widely cited 2018 study found that fenbendazole:

• inhibited the growth of human cancer cells
• disrupted microtubule dynamics
• activated tumor-suppressor pathways
• reduced glucose uptake in cancer cells

The drug also suppressed tumor growth in mouse xenograft models.
Study:
https://pubmed.ncbi.nlm.nih.gov/30093705/

Other research has demonstrated that benzimidazole drugs can induce apoptosis and inhibit tumor cell proliferation across multiple cancer types.

---

Evidence Specifically for Pancreatic Cancer

Direct studies of fenbendazole in pancreatic cancer are still limited.

However, researchers have studied closely related benzimidazole drugs, which share similar mechanisms. These drugs have shown the ability to:

• inhibit tumor growth
• disrupt microtubules
• block angiogenesis (blood vessel formation)

Because pancreatic cancer is notoriously resistant to many therapies, investigators continue to evaluate repurposed drugs such as benzimidazoles as potential adjunct therapies.

Still, human clinical evidence remains extremely limited, and much of the available data is preclinical.

---

Safety and Evidence Limitations

Patients considering fenbendazole should be aware of several important cautions.

1. Fenbendazole is not approved for human cancer treatment

Regulatory agencies have not approved fenbendazole for use in humans, and clinical data supporting its effectiveness against cancer are lacking.

2. Evidence is mostly preclinical

Most studies involve:

• cell culture experiments
• animal models

Human trials evaluating fenbendazole for cancer remain rare.

3. Possible side effects

Although fenbendazole is generally well tolerated in animals, case reports have documented liver injury in humans who self-administered the drug off-label.

---

Integrative Therapies That May Help Pancreatic Cancer Patients

While fenbendazole research continues, several evidence-based complementary approaches may support pancreatic cancer patients:

Nutrition and metabolic therapy

Anti-inflammatory diets and metabolic therapies are being studied as supportive strategies.

Physical activity

Exercise may help improve immune function, treatment tolerance, and quality of life.

Sleep and circadian rhythm support

Healthy sleep patterns can support immune and metabolic health.

Evidence-based supplements studied in pancreatic cancer

Examples sometimes explored in research include:

• curcumin
• omega-3 fatty acids
• medicinal mushrooms (turkey tail, reishi)
• melatonin

These therapies should always be discussed with an oncology team before use.

---

Bottom Line

Research on fenbendazole and pancreatic cancer remains at a very early stage.

Key points:

• Fenbendazole is a veterinary antiparasitic drug that disrupts cellular microtubules.
• Laboratory research suggests potential anticancer mechanisms including p53 activation and metabolic inhibition.
• Most evidence comes from preclinical studies, not human trials.
• More clinical research is needed to determine whether fenbendazole could play a role in cancer treatment.

Patients should always discuss any off-label therapies with their oncology team before considering them.

---

To Learn More About Repurposed Drugs for Cancer-

• Fenbendazole and Cancer: What the Research Really Shows”
• Mebendazole and Cancer: Anti-Tumor Mechanisms and Studies”
• Repurposed Drugs in Cancer Therapy: What the Science Shows”
• Metformin and Cancer: Why a Diabetes Drug Is Being Studied for Tumors
• Repurposed Drugs in Cancer Therapy: What the Science Shows
• Repurposed Drugs + Chemotherapy: Integrative Treatment

---

Research References

Dogra N, Kumar A, Mukhopadhyay T.
Fenbendazole acts as a microtubule destabilizing agent and causes cancer cell death.
https://pubmed.ncbi.nlm.nih.gov/30093705/

Son DS et al.
Antitumor potential of benzimidazole anthelmintics.
https://doi.org/10.4110/in.2020.20.e29

Makis W et al.
Fenbendazole as an anticancer agent: emerging evidence.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12215191/

Fenbendazole drug overview and safety.
https://en.wikipedia.org/wiki/Fenbendazole

Fenbendazole and Pancreatic Cancer Fenbendazole and Pancreatic Cancer